Neoadjuvant bevacizumab treatment for colorectal liver metastasis: A retrospective study

• Published in: Journal of clinical oncology Vol. 29; no. 4_suppl; p. 613
• Main Authors: García, P., Alvarez, S., Muñoz, A., Lopez, P., Riesco, M., Adeva Alfonso, J., Martin, M.
• Format: Journal Article
• Language: English
• Published: 01-02-2011
• ISSN: 0732-183X; 1527-7755
• DOI: 10.1200/jco.2011.29.4_suppl.613

Abstract only 613 Background: Patients with colorectal cancer (CRC) and liver metastases have a poor prognosis and may benefit from perioperative chemotherapy and disease resection. Bevacizumab is proven to improve outcomes in patients with metastatic CRC. Methods: This is a retrospective chart review performed in colorectal patients with liver metastases. All the patients were > 18 years old and have undergone bevacizumab therapy as neoadjuvant treatment. Results: 20 patients were analyzed. Baseline characteristics: median age 54.8 (49.2-65.8) years; male 45%; ECOG 0/1 40%/60%, 13 patients had metastatic disease at the time of their initial diagnosis. Median time from diagnosis of metastasis to surgery was 7.1 (5.4-9.6) months. Primary tumour locations were rectum (21.4%), colon (64.3%) and colon and rectum (14.3%). 80% and 20% of the patients received one and two lines of treatment before surgery, respectively. Mean cycles were 7.3±3.4 and 3.5±1.8 in first and second line, respectively. In 95% of the patients resection was curative. Mean number of resected metastasis was 3.4±2.8. 90%·of the patients achieved complete resection (R0) and 10% incomplete resection (R1). All the synchronous primary tumours (15) were resected. Among 16 valuable patients for pathological response, 1 (6.3%) experienced a pCR, 11 (68.8%) major response and 4 (25%) minor response. The median DFS was 12.2 months. The median OS was 48.9 months. Only one patient experienced grade 3-4 toxicity (rectal haemorraghe). Most frequent surgical complications were anastomotic filtration (8.7%) and wound infection (8.7%). Most frequent hepatic toxicities after surgery were steatohepatitis (25%) and sinusoidal dilatation (20%). Conclusions: These data provide evidence that neoadjuvant chemotherapy including bevacizumab can be safely administered in patients with mCRC. No significant financial relationships to disclose.